Suppr超能文献

追踪循环和组织驻留滤泡性淋巴瘤前体细胞中的种系突变。

Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors.

机构信息

Department of Medicine, Divisions of Hematology and Oncology, Stanford University Medical Center, Stanford, California.

Aix-Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.

出版信息

Cancer Discov. 2023 Jun 2;13(6):1310-1323. doi: 10.1158/2159-8290.CD-23-0111.

Abstract

UNLABELLED

Follicular lymphomas (FL) are characterized by BCL2 translocations, often detectable in blood years before FL diagnosis, but also observed in aging healthy individuals, suggesting additional lesions are required for lymphomagenesis. We directly characterized early cooperating mutations by ultradeep sequencing of prediagnostic blood and tissue specimens from 48 subjects who ultimately developed FL. Strikingly, CREBBP lysine acetyltransferase (KAT) domain mutations were the most commonly observed precursor lesions, and largely distinguished patients developing FL (14/48, 29%) from healthy adults with or without detected BCL2 rearrangements (0/13, P = 0.03 and 0/20, P = 0.007, respectively). CREBBP variants were detectable a median of 5.8 years before FL diagnosis, were clonally selected in FL tumors, and appeared restricted to the committed B-cell lineage. These results suggest that mutations affecting the CREBBP KAT domain are common lesions in FL cancer precursor cells (CPC), with the potential for discriminating subjects at risk of developing FL or monitoring residual disease.

SIGNIFICANCE

Our study provides direct evidence for recurrent genetic aberrations preceding FL diagnosis, revealing the combination of BCL2 translocation with CREBBP KAT domain mutations as characteristic committed lesions of FL CPCs. Such prediagnostic mutations are detectable years before clinical diagnosis and may help discriminate individuals at risk for lymphoma development. This article is highlighted in the In This Issue feature, p. 1275.

摘要

未标记

滤泡性淋巴瘤 (FL) 的特征是 BCL2 易位,通常在 FL 诊断前数年即可在血液中检测到,但也可见于衰老的健康个体中,这表明淋巴发生还需要其他病变。我们通过对 48 名最终发展为 FL 的患者的预诊断血液和组织标本进行超深度测序,直接对早期协同突变进行了特征分析。引人注目的是,CREBBP 赖氨酸乙酰转移酶 (KAT) 结构域突变是最常见的前体病变,并且在很大程度上区分了患有 FL 的患者(14/48,29%)与有或无检测到 BCL2 重排的健康成年人(0/13,P = 0.03 和 0/20,P = 0.007)。CREBBP 变体在 FL 诊断前中位时间为 5.8 年即可检测到,在 FL 肿瘤中克隆选择,并似乎仅限于定型 B 细胞谱系。这些结果表明,影响 CREBBP KAT 结构域的突变是 FL 癌前细胞 (CPC) 中的常见病变,具有区分有发展为 FL 风险的患者或监测残留疾病的潜力。

意义

我们的研究为 FL 诊断前的反复遗传异常提供了直接证据,揭示了 BCL2 易位与 CREBBP KAT 结构域突变的组合作为 FL CPC 的特征性定型病变。这些预诊断突变在临床诊断前数年即可检测到,可能有助于区分有患淋巴瘤风险的个体。本文在本期特色文章中重点介绍,第 1275 页。

相似文献

1
Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors.
Cancer Discov. 2023 Jun 2;13(6):1310-1323. doi: 10.1158/2159-8290.CD-23-0111.
2
5
Follicular lymphoma and diffuse large B-cell lymphoma with BCL2 and IRF4 rearrangements in adult patients.
Hum Pathol. 2023 Nov;141:22-29. doi: 10.1016/j.humpath.2023.08.008. Epub 2023 Aug 25.
6
The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.
Cancer Discov. 2017 Mar;7(3):322-337. doi: 10.1158/2159-8290.CD-16-1417. Epub 2017 Jan 9.
7
loss cooperates with overexpression to promote lymphoma in mice.
Blood. 2017 May 11;129(19):2645-2656. doi: 10.1182/blood-2016-08-733469. Epub 2017 Mar 13.

引用本文的文献

6
Circulating tumor DNA in lymphoma: technologies and applications.
J Hematol Oncol. 2025 Mar 11;18(1):29. doi: 10.1186/s13045-025-01673-7.
7
Liquid biopsy in detecting early non-small cell lung cancer.
J Liq Biopsy. 2023 Jul 27;1:100001. doi: 10.1016/j.jlb.2023.100001. eCollection 2023 Sep.
8
Primary thyroid B-cell lymphoma: molecular insights into its clonal evolution and relapse.
J Pathol. 2025 Feb;265(2):123-131. doi: 10.1002/path.6380. Epub 2024 Dec 26.
9
The POD24 challenge: where do we go from here for early progressors?
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):301-309. doi: 10.1182/hematology.2024000662.
10
Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot.
Am J Hematol. 2025 Feb;100(2):218-228. doi: 10.1002/ajh.27533. Epub 2024 Nov 20.

本文引用的文献

1
Distinction of lymphoid and myeloid clonal hematopoiesis.
Nat Med. 2021 Nov;27(11):1921-1927. doi: 10.1038/s41591-021-01521-4. Epub 2021 Oct 18.
2
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
Cancer Discov. 2020 Mar;10(3):440-459. doi: 10.1158/2159-8290.CD-19-0116. Epub 2020 Jan 8.
4
Definitive radiotherapy for localized follicular lymphoma staged by F-FDG PET-CT: a collaborative study by ILROG.
Blood. 2019 Jan 17;133(3):237-245. doi: 10.1182/blood-2018-04-843540. Epub 2018 Nov 16.
5
gene mutations are frequently detected in in situ follicular neoplasia.
Blood. 2018 Dec 20;132(25):2687-2690. doi: 10.1182/blood-2018-03-837039. Epub 2018 Nov 6.
6
Somatic mutations precede acute myeloid leukemia years before diagnosis.
Nat Med. 2018 Jul;24(7):1015-1023. doi: 10.1038/s41591-018-0081-z. Epub 2018 Jul 9.
7
Prediction of acute myeloid leukaemia risk in healthy individuals.
Nature. 2018 Jul;559(7714):400-404. doi: 10.1038/s41586-018-0317-6. Epub 2018 Jul 9.
8
Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.
Leukemia. 2018 May;32(5):1261-1265. doi: 10.1038/s41375-018-0043-y. Epub 2018 Feb 8.
9
Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors.
Nat Cell Biol. 2017 Sep;19(9):1093-1104. doi: 10.1038/ncb3597. Epub 2017 Aug 21.
10
loss cooperates with overexpression to promote lymphoma in mice.
Blood. 2017 May 11;129(19):2645-2656. doi: 10.1182/blood-2016-08-733469. Epub 2017 Mar 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验